Quick Answer
Denali Therapeutics Inc. reported Cash and Equivalents of $205.33 million for fiscal year 2025.
Denali Therapeutics Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $205.33M | +17.4% |
| 2024 | $174.96M | +37.6% |
| 2023 | $127.11M | -41.7% |
| 2022 | $218.04M | -25.7% |
| 2021 | $293.48M | -42.1% |
| 2020 | $507.14M | +538.3% |
| 2019 | $79.45M | +3.0% |
| 2018 | $77.12M | -64.7% |
| 2017 | $218.38M | +448.0% |
| 2016 | $39.85M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $90.96M | +0.4% | -35.6% |
| June 30, 2025 | $141.21M | +89.1% | +148.0% |
| March 31, 2025 | $56.95M | -6.0% | -67.5% |
| December 31, 2024 | $174.96M | +37.6% | +93.0% |
| September 30, 2024 | $90.64M | -38.8% | +21.4% |
| June 30, 2024 | $74.68M | -43.4% | +23.3% |
| March 31, 2024 | $60.57M | -11.1% | -52.3% |
| December 31, 2023 | $127.11M | -41.7% | -14.1% |
- Denali Therapeutics Inc. showed an increase of +17.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2016–2025 period, Denali Therapeutics Inc.’s cash and equivalents has grown by 415.2% (from $39.85 million to $205.33 million).
- The most recent figure is from Denali Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: